

**Publisher Address**

Bioexcel Publishing Ltd,

6 Green Lane Business Park,

238 Green Lane,

New Eltham,

London, SE9 3TL, UK

# TERMS AND CONDITIONS FOR PUBLICATION (TCP)

*Instructions for the corresponding author:* This document should be completed by the corresponding author on behalf of the authors listed in Appendix A of this document and the submitted manuscript. Please complete one copy of this form for each manuscript and return to the Editorial office:

dic.editorial@bioexcelpublishing.com

|  |
| --- |
| Corresponding author contact details |
| Title (Mr, Mrs, Ms, Professor, other) |  |
| First name |  |
| Initials |  |
| Last name |  |
| Email address |  |
| Affiliation (full address including ZIP/postal code and Country) |  |

These *Terms and Conditions for Publication* (‘TCP’) apply to authors of all materials submitted to the journal called *Drugs in Context* as part of the publication process (‘the Work’). Articles are published at <http://www.drugsincontext.com> (the ‘Site’) that is owned by Bioexcel Publishing Ltd (the ‘Publisher’). The Site is operated by the Publisher, a company registered in England6 Green Lane Business Park, 238 Green Lane, New Eltham, London, SE9 3TL, UK.

By completing this form and submitting a manuscript for publication, the authors of the submitted manuscript agree to be bound by the TCP. The TCP expressly incorporate the Site’s Privacy policy (found here: <http://www.drugsincontext.com/privacy-policy>) and the Website Terms and Conditions (found here: <http://www.drugsincontext.com/terms-conditions>).

## 1. Authors listed in the submitted manuscript (Appendix A)

1.1 All persons designated as authors are listed in Appendix A and should meet the criteria for authorship set out by the [International Committee of Medical Journal Editors](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two) (ICMJE) and all those who qualify will be listed in the citation. By signing this document, you hereby assert your moral rights to be identified as author of the Work according to the UK Copyright Designs & Patents Act 1988. The author retains the right to be identified as the author whenever and wherever the article is published.

## 2. Disclosure of Potential Conflicts of Interest

2.1 Please kindly note that *Drugs in Context* uses the ICMJE Conflict of Interest form (found here: <http://www.drugsincontext.com/submission>). The form is designed to be completed and stored electronically. Each author should submit a separate form and is responsible for accuracy.

## 3. Originality

3.1 You warrant that the Work is original and unpublished, is not under consideration for publication elsewhere, does not infringe upon the intellectual property rights of any other person or entity and cannot be construed as plagiarising any other published work and contains no statement that is abusive, defamatory, libelous, obscene, fraudulent, nor in any way infringes upon the rights of others, nor is in any other way unlawful or in violation of applicable laws.

## 4. Ethics

4.1 You warrant that all relevant ethics committee approvals have been obtained and complied with (stated in Methods section plus registration trial number).

## 5. Third party copyright

5.1 I acknowledge and obtain permission to re-use any copyrighted material contained in the manuscript. You must ensure that you have added an appropriate acknowledgment to any figure or table legend to say that it has been 'adapted from' or 'reproduced with permission from'. You must also cite the original source of the material in the legend. Please complete the following table:

|  |  |
| --- | --- |
|  | Please complete the boxes below: |
| I have obtained permission to re-use any copyrighted material contained in the manuscript. I have also added an appropriate acknowledgment to any figure or table legend to say that it has been 'adapted from' or 'reproduced with permission from'. I have also cited the original source of the material in the legend.I have kept electronic copies of all licenses obtained and any related correspondence. | Yes/NoFigure numbers:Table numbers: |
| I have not yet obtained the necessary permissions for re-use of figures/tables. I will do this now and will have them completed when I submit a revised manuscript. I will add the necessary acknowledgments to the figure/table legends at that time. (Note that we cannot publish any article until this is done.) | Yes/NoFigure numbers:Table numbers: |

5.2 *Drugs in Context* is a signatory to the Scientific Technical and Medical (‘STM’) Association Publishers’ Permissions Guidelines, which facilitates limited re-use of each other’s copyright material: <http://www.stm-assoc.org/permissions-guidelines/>. You can check this site for guidance on usage limits and the most recent list of all publishers who are signatories, and whether or not they require formal permission to re-use their material.

## 6. Materials supplied

6.1 The Publisher is under no obligation to return any items that are sent to the Publisher during the publishing process including original photos, slides, x-rays, etc., but the Publisher will endeavor to do so.

## 7. Funding source disclosure

7.1Please disclose all sources of funding for this article and if applicable, the study it describes, and provide all relevant information about the role of the funder in the preparation of the manuscript or the conduct of the study if applicable.

## 8. Copyright

8.1 Publicly funded research articles are published under the terms of Creative Commons License Deed CC BY 4.0 and privately funded research articles are published under the terms of Creative Commons License Deed CC BY NC ND 4.0. Please read more about our copyright policy here: [http://www.drugsincontext.com/faqs/ - q8](http://www.drugsincontext.com/faqs/#q8)<http://www.drugsincontext.com/about>

## 9. Article type

9.1 Please indicate which category best describes your article type:

|  |  |
| --- | --- |
| Original research |   |
| Review |   |
| Letter-to-the-Editor |   |
| Case report |   |
| Case series |  |
| Editorial/Opinion |   |
| Commentary |  |
| Conference report |   |
| Educational section |   |

9.2 **Specialist section**: please indicate the *primary* section in which you’d like your article to be published. If you think that your article should also be published in other sections of the journal, please indicate your choice/s below.

|  |  |  |
| --- | --- | --- |
| **Section** | **Primary section** | **Secondary sections** |
| Analgesia and anaesthesiology |  |  |
| Cardiology and cardiovascular disease |   |   |
| Dermatology |   |   |
| Endocrinology |   |   |
| Gastroenterology |   |   |
| Geriatrics |   |   |
| Haematology and oncology |   |   |
| Health economics and outcomes research |   |   |
| Immunology |   |   |
| Infectious disease |   |   |
| Musculoskeletal disease |   |   |
| Nephrology and urology |   |   |
| Neurology |   |   |
| Ophthalmology |   |   |
| Paediatrics |   |   |
| Primary care |   |   |
| Psychiatry |   |   |
| Rare diseases and orphan drugs |  |  |
| Respiratory diseases |   |   |
| Women’s health |   |   |

## 10. Payment terms

10.1 The author processing charge (APC) for is £2000, $2700, €2400, per article (plus VAT, if applicable).

10.2 Case reports, Editorials, Opinions and Commentaries qualify for a 50% APC discount. Letters-to-the-Editor are published free of charge.

10.3 Waivers can be made available for authors from developing countries. Please send an email inquiry to the Editorial Office for further information. Waivers (either to authors from developing countries or to Associate Editors) cannot be granted to papers with industrial funding.

10.4 There are no charges for submission, colour figures or page number excess.

10.5 On acceptance for publication, following peer review, an invoice will be raised for the APC on 14-day payment terms.

**11. Invoice details**

11.1 Please note that the Invoice for the APC will be sent by email.

|  |  |
| --- | --- |
| Name and email address of person to whom the invoice should be sent |  |
| Billing name (individual, institution or company) |  |
| Billing address line 1 |  |
| Billing address line 2 |  |
| Billing town/city |  |
| Billing ZIP/Postal code |  |
| Billing country |  |
| Purchase order number  |  |

**12. Acceptance of these terms on behalf of authors listed in the submitted manuscript**

12.1 Please add your name here to indicate that you have read and agree to the contents this the form.

12.2 Date:

**Appendix A – Author list and contact details**

Please kindly note that author email addresseses will be added to the Publisher’s database for publication alerts. Submission is not complete if the table below is not completed.

|  |  |  |  |
| --- | --- | --- | --- |
| Title (Dr, Mr, Mrs, Ms, Professor, Other) | First name | Last name | Email address |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |